Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
213 patients initially treated with TARE or Atezo/Bev between 2016 and 2023.
I · Intervention 중재 / 시술
Transarterial radioembolization
C · Comparison 대조 / 비교
atezolizumab
O · Outcome 결과 / 결론
No significant differences in Child-Pugh score aggravation of ≥ 2 were observed between the TARE group (14.4 %) and the Atezo/Bev group (25 %) (P = 0.08). [CONCLUSION] For patients with preserved liver function and locally advanced HCC involving segmental or lobar PVTT, TARE may be preferable to Atezo/Bev.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[PURPOSE] The purpose of this study was to compare transarterial radioembolization (TARE) and atezolizumab plus bevacizumab (Atezo/Bev) in treatment-naïve patients with hepatocellular carcinoma (HCC)
- p-value P < 0.01
- 95% CI 0.28-0.85
APA
Park Y, Cho Y, et al. (2026). Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.. Diagnostic and interventional imaging, 107(1), 25-37. https://doi.org/10.1016/j.diii.2025.09.002
MLA
Park Y, et al.. "Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.." Diagnostic and interventional imaging, vol. 107, no. 1, 2026, pp. 25-37.
PMID
40998641 ↗
Abstract 한글 요약
[PURPOSE] The purpose of this study was to compare transarterial radioembolization (TARE) and atezolizumab plus bevacizumab (Atezo/Bev) in treatment-naïve patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) without extrahepatic metastasis.
[MATERIAL AND METHODS] This multicenter retrospective study evaluated 213 patients initially treated with TARE or Atezo/Bev between 2016 and 2023. The primary outcome was overall survival, and the secondary outcomes were progression-free survival, objective response rate, and safety. Baseline characteristics were adjusted using inverse probability treatment weighting or propensity score matching.
[RESULTS] Deaths occurred in 36 out of 125 patients (28.8 %) in the TARE group and 57 out of 88 patients (64.8 %) in the Atezo/Bev group. The median overall survival was significantly longer in the TARE group (27.5 months) than in the Atezo/Bev group (8.6 months) (P < 0.01), consistent across analyses before matching (hazard ratio [HR], 0.38; 95% confidence interval [CI]: 0.25-0.58; P < 0.01), after inverse probability treatment weighting (HR, 0.49; 95 % CI: 0.28-0.85; P = 0.01), and after propensity score matching (HR, 0.40; 95% CI: 0.22-0.74; P < 0.01). In the PVTT subgroup involving segmental to lobar branches (Vp1-3), TARE demonstrated prolonged overall survival (HR, 0.36; 95 % CI: 0.20-0.63; P < 0.01), with no significant difference in patients with Vp4. The TARE and Atezo/Bev groups exhibited similar progression-free survival. No significant differences in objective response rate were found between TARE group (22.2-30.9 %) and Atezo/Bev group (30.6-30.9 %). Adverse events were less frequent in the TARE group than in the Atezo/Bev group. The incidence of grade ≥ 2 ascites and variceal bleeding were significantly lower in the TARE group (12.0 % and 1.7 %, respectively) than in the Atezo/Bev group (20.5 % and 8 %, respectively) (both P < 0.05). No significant differences in Child-Pugh score aggravation of ≥ 2 were observed between the TARE group (14.4 %) and the Atezo/Bev group (25 %) (P = 0.08).
[CONCLUSION] For patients with preserved liver function and locally advanced HCC involving segmental or lobar PVTT, TARE may be preferable to Atezo/Bev.
[MATERIAL AND METHODS] This multicenter retrospective study evaluated 213 patients initially treated with TARE or Atezo/Bev between 2016 and 2023. The primary outcome was overall survival, and the secondary outcomes were progression-free survival, objective response rate, and safety. Baseline characteristics were adjusted using inverse probability treatment weighting or propensity score matching.
[RESULTS] Deaths occurred in 36 out of 125 patients (28.8 %) in the TARE group and 57 out of 88 patients (64.8 %) in the Atezo/Bev group. The median overall survival was significantly longer in the TARE group (27.5 months) than in the Atezo/Bev group (8.6 months) (P < 0.01), consistent across analyses before matching (hazard ratio [HR], 0.38; 95% confidence interval [CI]: 0.25-0.58; P < 0.01), after inverse probability treatment weighting (HR, 0.49; 95 % CI: 0.28-0.85; P = 0.01), and after propensity score matching (HR, 0.40; 95% CI: 0.22-0.74; P < 0.01). In the PVTT subgroup involving segmental to lobar branches (Vp1-3), TARE demonstrated prolonged overall survival (HR, 0.36; 95 % CI: 0.20-0.63; P < 0.01), with no significant difference in patients with Vp4. The TARE and Atezo/Bev groups exhibited similar progression-free survival. No significant differences in objective response rate were found between TARE group (22.2-30.9 %) and Atezo/Bev group (30.6-30.9 %). Adverse events were less frequent in the TARE group than in the Atezo/Bev group. The incidence of grade ≥ 2 ascites and variceal bleeding were significantly lower in the TARE group (12.0 % and 1.7 %, respectively) than in the Atezo/Bev group (20.5 % and 8 %, respectively) (both P < 0.05). No significant differences in Child-Pugh score aggravation of ≥ 2 were observed between the TARE group (14.4 %) and the Atezo/Bev group (25 %) (P = 0.08).
[CONCLUSION] For patients with preserved liver function and locally advanced HCC involving segmental or lobar PVTT, TARE may be preferable to Atezo/Bev.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Hepatocellular
- Liver Neoplasms
- Male
- Female
- Bevacizumab
- Retrospective Studies
- Portal Vein
- Antibodies
- Monoclonal
- Humanized
- Middle Aged
- Aged
- Embolization
- Therapeutic
- Venous Thrombosis
- Antineoplastic Agents
- Immunological
- Atezolizumab
- Hepatocellular carcinoma
- Portal vein tumor thrombosis
- Transarterial radioembolization
같은 제1저자의 인용 많은 논문 (5)
- A tumor-targeted heptamethine cyanine dye induces suppression of progesterone receptor activity to treat hormone receptor-positive breast cancer.
- Quantitative Assessment of Cannula Kinematics in Liposuction Surgical Procedures Using a Marker-Based Tracking System.
- Apoptosis and Metabolic Reprogramming by RHART in Hepatocellular Carcinoma Through the CPSF6/MCT4/c-Myc Signaling In Vitro and In Vivo.
- Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model.
- Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.